MAIA AMEX
MAIA Biotechnology, Inc.
1W: -0.8%
1M: -13.1%
3M: -18.5%
YTD: -25.6%
1Y: -28.3%
3Y: -26.1%
$1.19
+0.02 (+1.71%)
Weekly Expected Move ±7.5%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.6M
Congress—
ETF Holdings—
Key Statistics
Market Cap$72.4M
52W Range0.87-3.19
Volume404,975
Avg Volume650,169
Beta0.26
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOVlad Vitoc
Employees13
SectorHealthcare
IndustryBiotechnology
IPO Date2022-07-28
WebsiteMAIABiotech.com
444 West Lake Street
Chicago, IL 60606
US
Chicago, IL 60606
US
312 416 8592
About MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Latest News
12 Health Care Stocks Moving In Thursday's After-Market Session
MAIA Biotechnology expects $33M capital raise to fund Phase 3 trial of anticancer therapy
Crude Oil Surges Over 6%; Target Profit Tops Views
12 Health Care Stocks Moving In Tuesday's Intraday Session
Dow Dips 900 Points; Best Buy Posts Upbeat Earnings
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| CHAOUKI STEVEN M | A-Award | 32,774 | $1.18 | 2026-09-30 |
| Theagene Jean-Manass | A-Award | 32,012 | $1.18 | 2026-09-30 |
| Smith Stan | A-Award | 38,871 | $1.18 | 2026-09-30 |
| Luput Cristian | A-Award | 33,536 | $1.18 | 2026-09-30 |
| Louie Ngar Yee | A-Award | 39,634 | $1.18 | 2026-09-30 |